Status:

RECRUITING

MEthylphenidate in ADHD - Addiction(s) Comorbidity: Value of Adding a Cognitive Remediation Program to Improve Short- and Medium-term Therapeutic Response

Lead Sponsor:

Nantes University Hospital

Conditions:

ADHD-add

Eligibility:

All Genders

15-99 years

Phase:

NA

Brief Summary

MEthylphenidate in ADHD - Addiction(s) comorbidity: benefit of adding a cognitive remediation program to improve short- and medium-term therapeutic response

Detailed Description

It seems essential to optimize the therapeutic management of patients suffering from ADHD/addiction(s) comorbidity by specifically targeting their neuropsychological deficits, in addition to the pharm...

Eligibility Criteria

Inclusion

  • Age over 15 (patients treated in the "adult" stream);
  • Diagnosis of ADHD confirmed by DIVA-5 interview (for patients over 18) or Young DIVA-5 (for patients between 15 and 17) following a specialized ADHD-addiction(s) consultation;
  • Indication for MPH treatment according to European recommendations (J. J. S. Kooij et al., 2019) and absence of contraindications (particularly cardiological);
  • Presence of at least one comorbid addictive disorder (TUS and/or AC);
  • Having given their consent to take part in the study;
  • Being affiliated to the French social security system or benefiting from such a system.

Exclusion

  • Presence of disorders of the higher functions or difficulties in reading or writing the French language making it impossible to collect data;
  • Pregnant or breast-feeding woman;
  • Person deprived of liberty;
  • Person under compulsory psychiatric care;
  • Participation in another interventional research protocol involving another psychotherapeutic or pharmacological intervention that may have an impact on clinical outcome;
  • Guardianship or safeguard of justice.

Key Trial Info

Start Date :

December 11 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 11 2029

Estimated Enrollment :

248 Patients enrolled

Trial Details

Trial ID

NCT06906328

Start Date

December 11 2025

End Date

December 11 2029

Last Update

December 23 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

CHRU Brest

Brest, Brittany Region, France, 29609

2

EPSM du Finistère Sud

Quimper, Brittany Region, France, 29000

3

EPSM Georges Daumézon (Fleury-les-Aubrais, Loiret)

Fleury-les-Aubrais, Centre-Val de Loire, France, 45400

4

CHRU de Tours

Tours, Centre-Val de Loire, France, 37000

MEthylphenidate in ADHD - Addiction(s) Comorbidity: Value of Adding a Cognitive Remediation Program to Improve Short- and Medium-term Therapeutic Response | DecenTrialz